Amgen Inc. has won approval for the second medicine in a new class of biotech drugs that reduce artery-clogging cholesterol more than older statin drugs that have been used for decades.
The drug Repatha could eventually help millions of Americans who face increased risks of heart disease because they cannot control their cholesterol with existing drugs. But concerns about the injectable medication's price tag and long-term benefits will likely limit its use in the near term.
Continue Reading Below
The Food and Drug Administration said Thursday it approved the drug for two groups of patients. First, for patients with extremely high levels of bad cholesterol due to an inherited disorder. Second, for patients with a history of heart attack and stroke who are not able to control their cholesterol levels with older drugs.